These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37957160)

  • 1. Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia.
    Chapman LAC; Aubry M; Maset N; Russell TW; Knock ES; Lees JA; Mallet HP; Cao-Lormeau VM; Kucharski AJ
    Nat Commun; 2023 Nov; 14(1):7330. PubMed ID: 37957160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Jentsch PC; Anand M; Bauch CT
    Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2.
    Kraay ANM; Gallagher ME; Ge Y; Han P; Baker JM; Koelle K; Handel A; Lopman BA
    J R Soc Interface; 2022 Sep; 19(194):20220477. PubMed ID: 36067790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France.
    Paireau J; Charpignon ML; Larrieu S; Calba C; Hozé N; Boëlle PY; Thiebaut R; Prague M; Cauchemez S
    BMC Infect Dis; 2023 Mar; 23(1):190. PubMed ID: 36997873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Johnson R; Djaafara B; Haw D; Doohan P; Forchini G; Pianella M; Ferguson N; Smith PC; Hauck KD
    Vaccine; 2023 Mar; 41(11):1885-1891. PubMed ID: 36781331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups.
    Kelly SL; Le Rutte EA; Richter M; Penny MA; Shattock AJ
    Infect Dis Ther; 2022 Oct; 11(5):2045-2061. PubMed ID: 36094720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis.
    Marcellusi A; Fabiano G; Sciattella P; Andreoni M; Mennini FS
    Clin Drug Investig; 2022 Mar; 42(3):237-242. PubMed ID: 35218000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on the Use of Innovative Surveillance Strategies Implemented for COVID-19 to Prevent Mosquito-Borne Disease Emergence in French Polynesia.
    Aubry M; Cao-Lormeau VM
    Viruses; 2022 Feb; 14(3):. PubMed ID: 35336867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
    Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
    Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels.
    Giardina J; Bilinski A; Fitzpatrick MC; Kendall EA; Linas BP; Salomon J; Ciaranello AL
    JAMA Netw Open; 2022 Feb; 5(2):e2147827. PubMed ID: 35157056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021.
    Ainslie KEC; Backer JA; de Boer PT; van Hoek AJ; Klinkenberg D; Korthals Altes H; Leung KY; de Melker H; Miura F; Wallinga J
    Euro Surveill; 2022 Nov; 27(44):. PubMed ID: 36330824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.